Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
Healthcare
$8.23 -0.67%
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
52W Low $6.44High $17.15
Volume 0.81M
Average 0.17M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$19.27M
FY 2025 · Annual
Investing Cash Flow
$40.35M
FY 2025 · Annual
-30.7% YoYFinancing Cash Flow
-$26.62M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| Deferred Income Tax | 345K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.99M | 26.97M | 28.22M | 26.8M | 18.57M |
| Change in Working Capital | (13.69M) | 6.79M | 8.02M | 7.13M | 39.91M |
| Accounts Receivables | (24.3M) | 11.8M | 9.42M | 973K | 31.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.77M | (4.63M) | (1.15M) | (414K) | (1.31M) |
| Other Working Capital | 6.84M | (372K) | (243K) | 6.57M | 9.46M |
| Other Non-Cash Items | (1.98M) | 242K | (7.95M) | 1.02M | (946K) |
| Operating Cash Flow | (70M) | (84.78M) | (103.15M) | (78.76M) | (19.27M) |
| Capital Expenditures | (750K) | (2.13M) | (9.06M) | (17.95M) | (12.9M) |
| Acquisitions (Net) | (37.74M) | (54.9M) | 44.52M | 0 | 0 |
| Purchases of Investments | (307.35M) | (171.45M) | (373.39M) | (307.28M) | (209.63M) |
| Sales of Investments | 345.09M | 228.47M | 328.87M | 383.47M | 262.87M |
| Other Investing Activities | 37.74M | 54.9M | (44.52M) | 0 | 0 |
| Investing Cash Flow | 36.99M | 54.9M | (53.58M) | 58.24M | 40.35M |
| Debt Repayment | 0 | 0 | 199.68M | (27.48M) | (26.49M) |
| Common Stock Issued | 3.61M | 21.26M | 2.21M | 147K | 145K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (534K) | (1.23M) | (3.76M) | (294K) | (277K) |
| Financing Cash Flow | 3.08M | 20.03M | 198.13M | (27.63M) | (26.62M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.93M) | (9.85M) | 41.39M | (48.16M) | (5.54M) |
| Free Cash Flow | (70.75M) | (86.91M) | (112.21M) | (96.71M) | (32.17M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$81.9M
+ D&A$5.1M
+ Stock-Based Comp$18.6M
+ Deferred Tax$0
+ Working Capital$39.9M
- Other Non-Cash-$946.0K
= Operating Cash Flow-$19.3M
- Capex-$12.9M
= Free Cash Flow-$32.2M
Analysis
FY2025 free cash flow is -$32.2M. FCF conversion is 39.3% of net income. Operating cash flow was -$19.3M, with capex of -$12.9M. The largest bridge item is Working Capital at $39.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 29, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does ENTA generate free cash flow?
Enanta Pharmaceuticals, Inc. (ENTA) generated -$32.17M of free cash flow in fiscal 2025.
How much operating cash flow does ENTA produce?
Operating cash flow was -$19.27M, before capital expenditures of $12.90M.
Continue the stock analysis
Jump to another research area for this company.